The strongest version of this narrative highlights the dynamic interplay between regulatory agencies, pharmaceutical companies, and scientific evidence in shaping biotech advancements. The FDA’s reconsideration of compounded peptides suggests a potential shift toward greater flexibility, acknowledging the role of compounding pharmacies in addressing unmet medical needs. Meanwhile, Roche’s additional trial for Elevidys and Eli Lilly’s progress with Foundayo underscore the high stakes of drug deve...